Supplementary Material from mTOR Inhibition Specifically Sensitizes Colorectal Cancers with &lt;i&gt;KRAS&lt;/i&gt; or &lt;i&gt;BRAF&lt;/i&gt; Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1